1. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006; 20:581–607. vi
2. Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al. Mucormycosis in hematologic patients. Haematologica. 2004; 89:207–214.
3. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995; 21:361–369.
4. Thomson SR, Bade PG, Taams M, Chrystal V. Gastrointestinal mucormycosis. Br J Surg. 1991; 78:952–954.
5. Suh IW, Park CS, Lee MS, Lee JH, Chang MS, Woo JH, et al. Hepatic and small bowel mucormycosis after chemotherapy in a patient with acute lymphocytic leukemia. J Korean Med Sci. 2000; 15:351–354.
6. Hagspiel KD, Kempf W, Hailemariam S, Marincek B. Mucormycosis of the liver: CT findings. AJR Am J Roentgenol. 1995; 165:340–342.
7. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41:634–653.
8. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases. Leuk Lymphoma. 2004; 45:1351–1360.
9. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988; 319:593–598.
10. Lee JH, Ha HK, Yoo E, Yang SK, Min YI, Auh YH. CT and sonographically guided biopsy in a patient with intestinal mucormycosis. AJR Am J Roentgenol. 2000; 175:129–131.